Literature DB >> 28514463

Pediatric Psoriasis Comorbidity Screening Guidelines.

Emily Osier1, Audrey S Wang2, Megha M Tollefson3, Kelly M Cordoro4, Stephen R Daniels5, Andrew Eichenfield6, Joel M Gelfand7, Alice B Gottlieb8, Alexa B Kimball9, Mark Lebwohl10, Nehal N Mehta11, Amy S Paller12, Jeffrey B Schwimmer13, Dennis M Styne14, Abby S Van Voorhees1, Wynnis L Tom15, Lawrence F Eichenfield15.   

Abstract

Importance: Psoriasis is a complex inflammatory skin condition associated with serious medical comorbidities in adults, including obesity, hypertension, dyslipidemia, type 2 diabetes mellitus, psoriatic arthritis, nonalcoholic fatty liver disease, depression, anxiety, and decreased quality of life. Because psoriasis begins in childhood in almost one-third of patients, early identification of risk may be critical to minimizing effects on future health. Objective: To develop the first set of guidelines for comorbidity screening for patients with pediatric psoriasis based on current evidence. Evidence Review: A literature review was performed using PubMed from January 1999 through December 2015. Limiting the search to human studies published in English and removing reviews and editorials produced 153 relevant manuscripts. An expert panel in psoriasis, pediatric dermatology, pediatric rheumatology, pediatric gastroenterology, pediatric endocrinology, and adult and pediatric cardiology used the patient-centered Strength of Recommendation Taxonomy (SORT) method to evaluate and grade the quality of evidence. Findings: Because of the limited number of pediatric studies published on these topics, the strength of the panel's recommendations is classified as SORT level C expert consensus recommendations. The majority of recommendations coincide with those endorsed by the American Academy of Pediatrics for the general pediatric patient but with added attention to signs and symptoms of arthritis, depression, and anxiety. The panel also identified key areas for further investigation. Conclusions and Relevance: Patients with pediatric psoriasis should receive routine screening and identification of risk factors for associated comorbidities. These guidelines are relevant for all health care providers caring for patients with pediatric psoriasis, including primary care clinicians, dermatologists, and pediatric specialists. Because these are the first pediatric guidelines, re-review and refinement will be necessary as studies further detail, and possibly stratify, risk in affected children.

Entities:  

Mesh:

Year:  2017        PMID: 28514463      PMCID: PMC5748031          DOI: 10.1001/jamadermatol.2017.0499

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  49 in total

1.  Prevalence of Obesity Among Adults and Youth: United States, 2011-2014.

Authors:  Cynthia L Ogden; Margaret D Carroll; Cheryl D Fryar; Katherine M Flegal
Journal:  NCHS Data Brief       Date:  2015-11

Review 2.  The psychosocial burden of psoriasis.

Authors:  Alexa B Kimball; Christine Jacobson; Stefan Weiss; Mary G Vreeland; Ying Wu
Journal:  Am J Clin Dermatol       Date:  2005       Impact factor: 7.403

Review 3.  Systemic treatments for severe pediatric psoriasis: a practical approach.

Authors:  Ann L Marqueling; Kelly M Cordoro
Journal:  Dermatol Clin       Date:  2013-04       Impact factor: 3.478

4.  Evaluating the strength of clinical recommendations in the medical literature: GRADE, SORT, and AGREE.

Authors:  Mayra Buainain de Castro Maymone; Stephanie D Gan; Michael Bigby
Journal:  J Invest Dermatol       Date:  2014-10       Impact factor: 8.551

Review 5.  Lipid screening and cardiovascular health in childhood.

Authors:  Stephen R Daniels; Frank R Greer
Journal:  Pediatrics       Date:  2008-07       Impact factor: 7.124

Review 6.  Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis.

Authors:  April W Armstrong; Caitlin T Harskamp; Ehrin J Armstrong
Journal:  JAMA Dermatol       Date:  2013-01       Impact factor: 10.282

7.  Psoriasis comorbidities: results from the National Psoriasis Foundation surveys 2003 to 2011.

Authors:  April W Armstrong; Clayton Schupp; Bruce Bebo
Journal:  Dermatology       Date:  2012-10-26       Impact factor: 5.366

8.  SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease.

Authors:  Jeffrey B Schwimmer; Winston Dunn; Gregory J Norman; Perrie E Pardee; Michael S Middleton; Nanda Kerkar; Claude B Sirlin
Journal:  Gastroenterology       Date:  2010-01-11       Impact factor: 22.682

9.  Psoriasis and risk of type 2 diabetes among women and men in the United States: a population-based cohort study.

Authors:  Wenqing Li; Jiali Han; Frank B Hu; Gary C Curhan; Abrar A Qureshi
Journal:  J Invest Dermatol       Date:  2011-10-13       Impact factor: 8.551

Review 10.  A systematic review of worldwide epidemiology of psoriasis.

Authors:  I M Michalek; B Loring; S M John
Journal:  J Eur Acad Dermatol Venereol       Date:  2016-08-30       Impact factor: 6.166

View more
  16 in total

1.  Psoriasis and Cardiovascular Risk in Children: The Usefulness of Carotid Intima-Media Thickness.

Authors:  Iria Neri; Marcello Lanari; Marianna Fabi; Marco A Chessa; Davide Panizza; Ada Dormi; Anna Gazzano; Annalisa Patrizi; Federico Bardazzi; Alessandro Rocca; Emanuele Filice
Journal:  Pediatr Cardiol       Date:  2022-03-22       Impact factor: 1.838

2.  A retrospective cohort study to evaluate the development of comorbidities, including psychiatric comorbidities, among a pediatric psoriasis population.

Authors:  Amy S Paller; Jennifer Schenfeld; Neil A Accortt; Gregory Kricorian
Journal:  Pediatr Dermatol       Date:  2019-02-21       Impact factor: 1.588

3.  A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naïve CD4 T Lymphocytes.

Authors:  Sun-Hye Shin; Hee-Yeon Kim; Hee-Soo Yoon; Woo-Jae Park; David R Adams; Nigel J Pyne; Susan Pyne; Joo-Won Park
Journal:  Int J Mol Sci       Date:  2020-11-08       Impact factor: 5.923

Review 4.  Optimal Management of Plaque Psoriasis in Adolescents: Current Perspectives.

Authors:  Emmanuel Mahé
Journal:  Psoriasis (Auckl)       Date:  2020-11-27

5.  Recommendations for Management of Childhood Psoriasis.

Authors:  Bhumesh Kumar Katakam; Malathi Munisamy; T Narayana Rao; Minu Jose Chiramel; Maitreyee Panda; Sandeep Gupta; Ranugha Pss; K A Seetharam
Journal:  Indian Dermatol Online J       Date:  2021-11-25

6.  Association of Metabolic Comorbidities with Pediatric Psoriasis: A Systematic Review and Meta-Analysis.

Authors:  Soo Ick Cho; Ye Eun Kim; Seong Jin Jo
Journal:  Ann Dermatol       Date:  2021-05-04       Impact factor: 1.444

Review 7.  Therapeutic challenges in managing pediatric psoriasis.

Authors:  Yamila Goenaga-Vázquez; Kyle C Lauck; Adelaide A Hebert
Journal:  Int J Womens Dermatol       Date:  2020-10-10

8.  An Association of Pediatric Psoriasis with Metabolic Syndrome in Thai Children: 20 Years Retrospective Study.

Authors:  Parichat Mhusakunchai; Leelawadee Techasatian
Journal:  Psoriasis (Auckl)       Date:  2021-06-29

9.  Management of Paediatric Psoriasis by Paediatricians: A Questionnaire-Based Survey.

Authors:  Andreas Pinter; Nicole Mielke; Bartosz Malisiewicz; Roland Kaufmann; Anke König
Journal:  Dermatol Ther (Heidelb)       Date:  2020-05-18

Review 10.  FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review.

Authors:  Nida Aslam; Hajra Saleem; Salikh Murtazaliev; Sohail J Quazi; Safeera Khan
Journal:  Cureus       Date:  2020-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.